Good morning, today we're visualizing...
Oil's Hormuz Premium Is Leaking Out
Kirkland Is a $90B Brand
AMD Joins the $1T Club
Have feedback? Just hit reply!
Oil's Hormuz premium is leaking out. WTI crude spiked near $106 in mid-September as the Strait of Hormuz risk trade intensified. Now prices have backed off fast. By Sept. 22, WTI was around $90, down roughly 15% from the peak, after reports that Iran had offered a seven-day path to reopen the strait if Washington began easing its blockade. Hormuz matters because it is one of the world's most important oil chokepoints. When the market sees a path to reopening, the trade can move quickly.
WTI crude has started giving back a large chunk of its Hormuz risk premium.
The front-month futures price climbed through early September and peaked near $106 on Sept. 15. By Sept. 22, it was trading around $90, roughly 15% below that peak, with the latest move coming as reports pointed to a possible diplomatic path for reopening the Strait of Hormuz.
The key caveat is that the reopening proposal remains conditional. Kyodo, cited through SBS, reported that Iran offered to reopen the strait within seven days if Washington began easing its blockade of Iranian ports and halted military operations around the waterway. No agreement has been reached.
For markets, the reason this matters is straightforward: the Strait of Hormuz is one of the most important oil chokepoints in the world. EIA has estimated that roughly 20 million barrels per day of crude oil, condensate, and petroleum products flowed through the strait in recent normal conditions.
That makes Hormuz a direct line into oil prices, inflation expectations, Fed pricing, and risk appetite. If the market believes there is a credible path to reopening, oil can fall quickly and equities can catch a relief bid.
Kirkland is not just Costco's private label anymore. Costco says Kirkland Signature now represents about $90B of annual global revenue. That is more than Nike's FY2025 revenue. It is also slightly bigger than Procter & Gamble's reported FY2025 net sales. Private label has quietly become one of the biggest consumer brands in the world.
Costco's Kirkland Signature has become one of the largest consumer brands in the world.
In its fiscal 2025 annual report, Costco said Kirkland Signature now represents approximately $90 billion of annual revenue globally. That puts the private-label brand above Nike's $46.3 billion in FY2025 revenue and slightly above Procter & Gamble's $84.3 billion in FY2025 net sales.
The comparison is striking because Kirkland is not a standalone public company. It sits inside Costco, but its sales scale is already larger than many household-name consumer giants.
For investors, the point is simple: Costco's brand power is not limited to membership renewals and warehouse traffic. Kirkland has become a massive owned-brand engine inside the business.
AMD just joined the trillion-dollar club. The chipmaker's market cap has climbed from roughly $2.3B in 2015 to about $1T in 2026. That is one of the more dramatic comeback arcs in public markets. The AI trade has turned AMD from an old chip underdog into a trillion-dollar infrastructure story.
AMD crossed the $1 trillion market-cap milestone for the first time in September 2026, capping one of the more dramatic long-term comeback arcs in semiconductors.
The company was worth only about $2.3 billion in 2015. Since then, AMD has ridden a combination of CPU share gains, data-center momentum, and AI chip enthusiasm into the top tier of public-market valuations.
The chart shows the size of that re-rating: a long grind higher through the late 2010s, a pandemic-era surge, a 2022 reset, and then a sharp AI-driven climb into 2026.
The milestone matters because it reframes AMD's market identity. This is no longer just a cyclical chip recovery story. Investors are increasingly treating AMD as part of the core AI infrastructure trade.
Stock of the Day
MEDP: Medpace Holdings, Inc.
Medpace, a clinical research services leader, combines consistent double-digit revenue growth and high institutional ownership, making it a timely leader in Life Science Tools & CDMO.
The stock sits at its 52‑week high with strong short‑term relative strength (33.1% excess return over three months) while recent revenue reached roughly $707 million and GAAP diluted EPS exceeded $4, supported by heavy institutional sponsorship; that combination makes the current setup a timely one to monitor even though a verified breakout is absent.
Growth could decelerate: revenue and GAAP EPS are not accelerating despite positive year‑over‑year gains. Technical risk is elevated, with a Stage 3 topping classification and no verified breakout, which raises the chance of a stalled advance or distribution. High institutional ownership (91.25%) can amplify share moves if large holders rotate out, and demand for CRO/CDMO services remains tied to biopharma R&D spending cycles.
Not investment advice. Do your own research.
Note: This article does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.